LINKING genomic variants to traits is central to discovering the mechanisms of genetic diseases. To date, the National Human Genome Research Institute (NHGRI) has curated \>1750 publications of genome-wide association studies (GWAS) that considered at least 100,000 single nucleotide polymorphisms (SNP) ([@bib31]; [@bib42]). The adoption of high-throughput sequencing technology has facilitated the rapid identification of potentially causal variants. The 1000 Genomes Project has characterized ∼88 million variants by whole-genome sequencing (WGS) of 2504 individuals from 26 populations ([@bib1]). Such sequencing approaches to genomic association will soon enable discovery at a base-pair resolution. Meanwhile, statistical methods for GWAS have evolved from odds ratio tests, to generalized linear regression models (LMs), to more sophisticated multivariate linear mixed models (LMMs). LMM approaches have the capacity to correct population structures and sample relatedness ([@bib18]), thereby minimizing false positives due to allelic cosegregation. Consequently, the number of LMM-compatible computational tools for genetic studies is rapidly increasing, *e.g.*, ASReml, TASSEL, EMMA, QTLRel, FaST-LMM, DOQTL, GEMMA, and GMMAT ([@bib15]; [@bib24]; [@bib43]; [@bib9]; [@bib30]; [@bib12]; [@bib46]; [@bib8]).

While LMMs are efficient in correcting sample relatedness, response variables are restricted as numerical. Meanwhile, phenotypic traits in GWAS are often categorical, such as binary variables in case-control studies or multi-level ordered categorical variables which correspond to disease stages. To model discrete response variables in the context of mixed models for population relatedness correction, generalized LMMs (GLMMs) are required. [@bib8] published a method that handles a binary response variable in the context of a mixed model. However, multiple-level categorical variables are not supported. Current approaches commonly transform categorical variables into continuous variables to fit LMMs, following the assumption that the trait has constant residual variance. However, the constant residual variance assumption is often violated by a categorical trait, which can bias effect estimates.

The proliferation of multiple GWAS for a single disease has also generated a need for methods to systematically combine results from multiple studies. Such efforts, often pursued as meta-analyses, can dramatically boost statistical power through an increase in sample size ([@bib26]). However, association strengths of a given variant or a genetic locus typically fluctuate across studies, which may be due to different population compositions, environmental exposures, clinical reporting standards, and experimental platforms. As a result, it is often difficult or impossible to merge raw data from different studies into a single association model. Furthermore, a more general integration of prior information is often desirable, such as coexpression or other correlations between genes. Integration approaches with more flexibility are needed to address these issues.

To address these challenges, we created the Bayes-GLMM method that exploits the flexibility of a Bayesian modeling framework and the computing efficiency of the recently developed statistical programming language Stan (<http://mc-stan.org>; [@bib7]). As a Bayesian strategy, model parameters are assumed to be stochastic rather than fixed as in the case of frequentist approaches ([@bib14]). The stochastic nature of Bayesian modeling provides a coherent solution to combine published results of a related GWAS by configuring the prior distributions of the statistics of interest and computing posterior probabilities given new data ([@bib40]; [@bib34]; [@bib39]). Bayes-GLMM priors are determined from reported effect sizes and corresponding *P*-values, thereby allowing integration of published studies based on summary statistics. Bayes-GLMM is available as an R package for public use.

We applied Bayes-GLMM to the analysis of WGS association studies using resources made available by the Alzheimer's Disease Sequencing Project (ADSP). Alzheimer's disease (AD) is the most common form of dementia, predicted to affect 50 million people worldwide by 2020. Unfortunately, there is no known cure. AD is commonly divided into early-onset (EOAD) and late-onset (LOAD) disease. The known genetic causes of EOAD are relatively simple with mutations in amyloid precursor protein (*APP*) and APP-processing enzymes such as the presenilins (*e.g.*, *PSEN1*, *PSEN2*). However, the genetics of LOAD are poorly understood. Variations in apolipoprotein E (*APOE*) are the greatest genetic risk factor, with the ε*4* allele conferring a 30--50% increased risk for AD ([@bib6]). Recently, rare variants in triggering receptor expressed on myeloid cells 2 (*TREM2*) were identified that increase risk for AD ([@bib16]; [@bib22]). However, few other specific causative variants have been confirmed for AD, although numerous loci have associated by GWAS ([@bib17]; [@bib27], [@bib28]; [@bib21]; [@bib23]; [@bib19]; [@bib33]). The lack of causative variants severely hampers diagnosis, animal model creation, and the development of new therapies for LOAD. Here, we report four novel noncoding variants, identified through applying Bayes-GLMM to the ADSP WGS data set. Highlighting the potential of Bayes-GLMM, these putative causative variants provide new avenues for testing the role of novel genes/pathways in LOAD.

Materials and Methods {#s1}
=====================

Overview of the statistical models {#s2}
----------------------------------

Bayes-GLMM implemented GLMMs in a Bayesian framework. Bayesian models are defined by two parts: (1) a likelihood function that describes the data-generating process, and (2) the prior distributions of model parameters. Bayes-GLMM took LM, logistic regression model (logit-LM), and ordered logit-LM (ordered-logit-LM) as likelihoods functions of numerical, binary, and categorical traits, respectively.

### LMMs: {#s3}

In linear modeling, the numerical response variable *Y* was modeled in the LMM scheme:$$Y = X\beta + g\beta_{0} + u + e$$$$\beta \sim N\left( {0,1} \right)$$$$\beta_{0} \sim N\left( {0,1} \right)$$$$u \sim mvN\left( {0,\sigma_{g}^{2}K} \right)$$$$e \sim N\left( {0,\sigma_{e}^{2}} \right)$$$$\sigma_{g} \sim {in}v_{gamma{({2,~1})}}$$$$\sigma_{e} \sim {in}v_{gamma{({2,~1})}}.$$In the above equations, *X* was an *n*-by-*m* covariate matrix with sample size *n* and the number of conditional variables *m*. *β* was the corresponding parameter vector in length *m*. *g* was the numerical genotype of a variant coded as 0, 1, or 2; representing homozygous reference allele type, heterozygous, and homozygous alternative allele type, respectively. *β*~0~ was the variant's effect size. A standard normal, *N*(0, 1), was used for *β*~0~ of variants with no known effects. Further, *β* followed *N*(0, 1) in prior, and *σ*~g~ and *σ*~e~ followed inverse gamma distribution in priors. While a uniformly distributed effect prior may also be used, we found that a normally distributed prior reduced effect estimates by an average of 6% (Supplemental Material, Figure S1 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx)), which we viewed as a favorable shrinkage to reduce false positives in genome-wide association.

To model the sample relatedness, *u* was included as a random term that followed a multivariate normal distribution, with prior distribution $mvN\left( {0,\sigma_{g}^{2}K} \right)$ with expected mean vector 0 and covariance matrix *$\sigma_{g}^{2}$K*. $\sigma_{g}^{2}$ was the variance component and *K* was the kinship matrix of the samples. $mvN\left( {0,\sigma_{g}^{2}K} \right)$ was parameterized by the Cholesky factoring of *K* and *n* independent standard normal distributions:
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### GLMMs for binary variables: {#s4}

In logit-LM, the 0/1 response variable *Y~i~* followed a binomial distribution with a scalar parameter *π* representing the probability that *Y~i~* equaled 1. *π* was further transformed by the logit function and modeled in the linear model scheme:
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### GLMMs for ordered categorical variables: {#s5}

In ordered-logit-LM, the ordered categorical response variable *Y~i~* with *J* levels followed a multinomial distribution with a vector of parameters *π*, where *π~ij~* represents the probability that the *i*th observation falls in response category *j*. Cumulative distribution of *π* was logit-transformed and modeled in the linear model scheme:$$P\left( {Y_{i} \leq j} \right) = \pi_{i1} + \ldots + \pi_{ij}$$$$\text{logit}\left\lbrack {P\left( {Y_{i} \leq j} \right)} \right\rbrack = \theta_{j} - X\beta - g\beta_{0} + u~j = 1,\ldots,~J - 1$$$$\theta = 10*\text{cumsum}\left( \theta_{0} \right)$$$$\theta_{0} = \text{Dirichlet}(1).$$The cut-point parameters ($\theta$) in ordered categorical models comprise a vector of monotonically increasing real numbers. In our method, the increasing cut-point vector was specified by the cumulative sum (cumsum) of a primitive parameter $\theta_{0},$ which itself is a random sample of Dirichlet distribution, taking advantage of the fact that Dirichlet distribution samples are a vector of positive real numbers that always sum to 1.

### Modeling the prior information of variant effects: {#s6}

To integrate prior information of variant effects, Bayes-GLMM implemented an approach that allowed priors to only modulate information of the data under study. In this method, the prior distribution of variant effect was modeled by a hierarchical model, $\beta_{0} \sim N\left( {t*\sigma_{0},\sigma_{0}^{2}} \right),$ in which *t* represented prior information of the given variant and $\sigma_{0}$ represented the SD of the Gaussian model. *t* was further modeled by a normal distribution with an expected mean of the standardized effect size *prior* and the unit deviation. The variable *prior* was defined by the variant's prior effect size divided by its SE, which was often reported in published GWAS summary statistics. A standard normal, *N*(0, 1), was used for *β*~0~ of variants with no known effects:$$\beta_{0} \sim N\left( {t*\sigma_{0},\sigma_{0}^{2}} \right)$$$$t \sim N\left( {prior,1} \right)$$$$\sigma_{0} \sim {in}v_{gamma{({2,1})}}.$$We found this method of using priors appealing in three aspects: (1) it standardized the different interpretations of effect size from different statistical models, (2) it used information on both effect size and its SE, and (3) it softened the strong weight of priors from studies with unbalanced sample sizes.

Model estimations {#s7}
-----------------

Our models were built under Stan, which provides a flexible and efficient programming environment for statistical modeling. Inherited from Stan, Bayes-GLMM supported two methods for parameter estimation: limited-memory Broyden--Fletcher--Goldfarb--Shanno (L-BFGS) maximal likelihood estimation (MLE), and Hamilton Markov chain Monte Carlo (HMC) sampling. L-BFGS is in the family of quasi-Newton methods that approximates the original BFGS algorithm using a limited amount of computer memory ([@bib35]). The MLE method made a point estimation for each parameter that maximized the joint posterior of model parameters, whereas the Markov chain Monte Carlo (MCMC) sampling method captured a full posterior distribution for each parameter by iterative sampling. Significance of the estimated effect size *β*~0~ can be accessed by combing *β*~0~ and its SE, *SE*(*β~0~*). SEs of MLE were computed as the inverse of the square root of the diagonal elements of the observed Fisher information matrix ([@bib37]). A standardized *z* value was computed as *β*~0~/*SE*(*β~0~*), which led to a *P*-value that quantified the probability of obtaining the *β*~0~ by chance:$$SE\left( {\hat{\theta}}_{ML} \right) = \frac{1}{\sqrt{I\left( {\hat{\theta}}_{ML} \right)}}~$$$$I\left( \theta \right) = - \frac{d^{2}}{d\theta_{i}\theta_{j}}l\left( \theta \right)1 \leq i,~j \leq p.$$${\hat{\theta}}_{ML}$ was the MLE of model parameters, *I*(*θ*) was the Fisher information matrix, and *p* was the number of parameters.

In MCMC sampling, we drew 400 samples (200 as burn-in, 200 as effective) for each of three randomly-initiated Markov chains, which resulted in 600 effective samples in total. We used the Gelman--Rubin diagnostic ($\hat{R}$ in Stan) to assess convergence of multiple chains ([@bib13]). The *P*-value of variant effect using MCMC sampling results was reported as the tail probability ($P^{t}$) of the variant effect's posterior distribution:$$\left. P^{t} = 2 \ast \int\limits_{- \infty}^{0}P(\beta \middle| data)d\beta,\,\text{for}\,\text{mean}\,\left\lbrack P(\beta \middle| data) \right\rbrack > 0 \right.$$$$P^{t} = 2 \ast \left\lbrack {1 - \int\limits_{- \infty}^{0}P\left( \beta \middle| data \right)d\beta} \right\rbrack,\text{for}\,\text{mean}\left\lbrack P(\beta \middle| data) \right\rbrack < 0.$$Following the normality assumption, *P^t^* was computed by the same procedure as used to compute *P*-values of MLE estimations, while *SE*(*β~0~*) was taken as the SD of the variant effect's posterior distribution. We found that tail probabilities computed this way are consistent with the frequentist *P*-values under a generalized linear model (GLM) scheme (Figure S2 in [File S1](http://www.genetics.orglookup/suppl/doi:10.1534/genetics.117.300673/-/DC1/FileS1.docx)).

Kinship matrix {#s8}
--------------

We used *u* as a random term to account for the sample relatedness. *u* follows the normal distribution $mvN\left( {0,\sigma_{g}^{2}K} \right),$ where *K* was the kinship matrix of the samples. For each *K* entry, genotype-based relatedness for the sample pair, or the identical-by-state coefficient, was computed using the full spectrum of genomic variants in the ADSP samples. PLINK was used for fast kinship estimation on the massive genotype data.

LMMs in the frequentist scheme {#s9}
------------------------------

To compare the performances of our method to that of an LMM in the frequentist scheme in analyzing the ADSP data set, we built an LMM as follows:$$y_{i} = X_{i}\beta + u + e$$$$u \sim mvN\left( {0,\sigma_{g}^{2}K} \right)$$$$e \sim N(0,\sigma_{e}^{2}I).$$$y_{i}~$was the numerical mapping of the AD categories: no = 0, possible = 0.25, probable = 0.5, and definite = 1. $X$ was the covariate matrix including age and sex, *u* was the random term, and $e$ was the model residual. The LMM was estimated with QTLRel in R ([@bib9]).

Mouse strains, tissue harvesting, and sectioning {#s10}
------------------------------------------------

All experiments involving mice were conducted in accordance with policies and procedures described in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and were approved by the Institutional Animal Care and Use Committee (IACUC) at The Jackson Laboratory. All mice were bred and housed in a 12-/12-hr light/dark cycle. Male C57BL/6J mice (6 months old) were injected intraperitoneally with a lethal quantity of ketamine/xylazine according to IACUC-approved procedures. Mice were perfused with 1× PBS and whole brains were removed and fixed in 4% paraformaldehyde for 2 hr at 4°. Following fixation, the tissue was rinsed in 1× PBS, incubated in 10% sucrose for 8 hr at 4°, and then incubated in 30% sucrose overnight at 4°. Brains were then frozen in optimal cutting temperature compound and stored at −80° until sectioning. Frozen brains were sectioned at 25 µm and mounted on glass slides, which were stored at −80° until required for immunofluorescence staining.

Immunofluorescence {#s11}
------------------

Brain sections were incubated overnight at 4° in the following primary antibodies: rabbit polyclonal anti-PDGFA (1:50; Bioss Antibodies), sheep polyclonal anti-PRKAR1B (1:50; R&D Systems), goat anti-COL-IV (1:50; EMD Millipore), and goat anti-CD31 (1:50; R&D Systems). Sections were immersed in deionized water for 3 min at 37° and then treated with 0.5 mg/ml pepsin in 0.2N HCl for 15 min at 37°. Slides were then washed twice in 1× PBS for 10 min at room temperature. With the exception of anti-COL-IV, antibodies were diluted in 0.5% PBTB (1× PBS, 0.0.5% Triton X-100, and 0.5% BSA) containing 10% normal donkey serum. Anti-COL-IV was diluted in 0.5% PBS/Tween 20 (PBT). Sections were washed three times in 0.5% PBT and then incubated for 2 hr at room temperature with their respective secondary antibodies (donkey anti-rabbit Alexa Fluor 594, donkey anti-goat Alexa Fluor 488, and donkey anti-sheep Alexa Fluor 594 in a 1:1000 dilution; Life Technologies). All sections were then counterstained with DAPI (1:1000 in 1× PBS) and washed with 1× PBS prior to mounting with Aqua PolyMount. Images were taken using a Leica SP5 confocal microscope located within the imaging facility at The Jackson Laboratory.

Data availability {#s12}
-----------------

All ADSP genotype and phenotype data are available via dbGaP under study accession phs000572.v7.p4. C57BL/6J mice are available for purchase from The Jackson Laboratory (strain \#000664) at <https://www.jax.org/strain/000664>. The code used for analysis is available as Bayes-GLMM in a GitHub repository for public use at <https://github.com/xulong82/bayes.glmm>. Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) data are available as cited ([@bib29]). Additional information on associated variants can be found in [Table S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/2/TableS2.xlsx) and [Table S2](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/2/TableS2.xlsx).

Results {#s13}
=======

ADSP {#s14}
----

The development of Bayes-GLMM was motivated by the advent of the WGS association studies, such as the ADSP ([www.niagads.org/adsp](http://www.niagads.org/adsp); *Materials and Methods*). ADSP was initiated to discover novel genomic variants for LOAD. The WGS cohorts of ADSP contained 570 participants from 111 families. This family-based design generated profound sample relatedness that warranted a mixed-model approach. Furthermore, phenotypic traits were categorized into four levels of Alzheimer's diagnoses: no (*N* = 78), possible (*N* = 81), probable (*N* = 356), and definite (*N* = 55), which necessitated a generalized categorical model. Family pedigree, race, ethnicity, age, sex, and *APOE* ε*2*/ε*3*/ε*4* genotype were also reported for each participant. The population was 61% female. The interquartile range of sample ages was 67--80 years. In *APOE* genotypes, homozygous *APOE*ε*3* comprised 56.7% (*N* = 323) of the population, followed by 35.1% (*N* = 200) of *APOE*ε*3*/*APOE*ε*4*, 6.84% (*N* = 39) of *APOE*ε*2*/*APOE*ε*3*, 1.05% (*N* = 6) of *APOE*ε*2*/*APOE*ε*4*, and 0.351% (*N* = 2) of *APOE*ε*2*/*APOE*ε*2* ([Figure 1](#fig1){ref-type="fig"}). Individuals homozygous for *APOE*ε*4* were excluded from the study.

![Summary statistics of the ADSP WGS cohort. (A) AD diagnosis for 570 individuals across 111 families. (B) APOE allele-type composition. (C) Age distributions of individuals in each AD diagnostic category (left), sex composition in each category (middle), and *APOE* allele-type composition in each category (right).](51fig1){#fig1}

The additive effects of age, sex (female), and *APOE* allele types (ε*2*, ε*3*, and ε*4*) were tested with Bayes-GLMM together with the cut-points parameters of the ordered categorical model ([Figure 2](#fig2){ref-type="fig"}). To account for sample relatedness, kinship structure was computed from autosomal variants and included as the variance--covariance matrix of a random effect that followed a multivariate normal distribution (*Materials and Methods*). Model parameters were estimated by MCMC sampling. As expected, we observed that the *APOE*ε*4* allele significantly increased risk of AD (*P* = 0.00014), while the *APOE*ε*2* allele reduced risk (*P* = 0.0033) relative to the baseline *APOE*ε*3* allele. Sex was also a significant factor, with females at a higher risk (*P* = 0.032). Increasing age corresponded to a small but significant risk increase (*P* = 0.00036). The small effect size of age was a result of multiple factors: (1) the relatively large values for age as a model predictor (67--80 years), (2) a narrow age range, and (3) the possible longevity of nonaffected individuals. All covariate pairs were tested with fixed-effect interaction terms, but no significant interactions were observed (Figure S3 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx)).

![Bayes-GLMM estimation of model parameters by MCMC sampling of GLMM. Areas shown are 95% highest posterior density. (A) Posterior distributions of the ordered categorical model's cut points. Convergence diagnostics $\hat{R}$ of cut 1, cut 2, and cut 3 were 1.01, 1.00, and 1.03, respectively, which implies strong convergence. (B) Posterior distributions of the model covariate's effect sizes: age, sex, *APOE*ε*2*, and *APOE*ε*4*. $\hat{R}$ of age, sex, APOE/ε2, and APOE/ε4 were 1.00, 1.00, 1.01, and 1.00, respectively.](51fig2){#fig2}

GWAS of ADSP WGS cohort by Bayes-GLMM {#s15}
-------------------------------------

The ADSP consortium identified a total of 27.9 million SNPs from the WGS cohort, of which 10.3 million passed their quality check and had a minor allele frequency \>0.01 (Figure S4 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx)). Associations of the 10.3 million SNPs to AD status were tested by Bayes-GLMM in two steps ([Figure 3](#fig3){ref-type="fig"}). In the first step, a GLM (ordered categorical model) was applied to each of the 10.3 million variants without the random term. The purpose of this step was to perform a preliminary screen for potential candidate variants. Model parameters were estimated by the MLE method for computational efficiency. Variants with *P* \< 0.0001 were identified as potential candidate variants (*N* = 9726; [Figure 4A](#fig4){ref-type="fig"}). In the second step, candidate variants from the first step were tested with the full GLMM, including the random term to address sample relatedness. Model parameters were estimated by MCMC sampling to avoid the instability in estimating GLMM by MLE. Final *P*-values for every variant were obtained from their empirical posterior distributions ([Figure 4B](#fig4){ref-type="fig"}).

![Analysis overview of two-step GWAS analysis using Bayes-GLMM. Initial data (blue) were filtered and prescanned with a fixed linear model (green). Results were filtered by significance and scanned using the full GLMM (orange).](51fig3){#fig3}

![Association results for ADSP WGS cohort by Bayes-GLMM. (A) Results for 10.3 million genomic variants by Bayes-GLMM without kinship correction. Model parameters were estimated by MLE. Variants with *P* \< 0.0001, above the dashed line, were chosen for the full scan (9726 variants). (B) GWAS on filtered variants by GLMM with kinship correction. Model parameters were estimated by MCMC sampling. Dashed line was the cutoff of genome-wide significance (*P* \< 5 × 10^−8^).](51fig4){#fig4}

Top LOAD-associated variants from ADSP WGS {#s16}
------------------------------------------

We identified four variants in three independent loci with *P* \< 5 × 10^−8^, and 55 variants in 28 loci with *P* \< 1 × 10^−6^ ([Table 1](#t1){ref-type="table"}). The top two variants meet a stricter significance threshold of *P* \< 5 × 10^−9^ that would assume ∼10 million independent SNPs. Of the top 55 variants, 52 were associated with an increased LOAD risk. Furthermore, variants with strong effects tended to occur at a lower allele frequency, suggesting that these variants might be under negative selection ([Figure 5](#fig5){ref-type="fig"}). The top 55 variants were mapped to 146 genomic annotations using Ensembl Variant Effect Predictor (variants commonly mapped to multiple annotations): 73 were in introns, 31 were in intergenic regions, 27 were upstream of genes (within 5 kb upstream from the 5′ end), 11 were downstream of genes (within 5 kb downstream from the 3′ end), and 4 were regulatory regions ([Table S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/2/TableS2.xlsx)). The 73 intronic annotations mapped to 19 variants and 18 unique genes. Of the 18 genes, 12 appeared in the NHGRI GWAS catalog as being associated with disease ([@bib42]) ([Table S2](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/2/TableS2.xlsx)). Associated traits of the 12 genes included obesity-related traits (*PTPRD*, *SORCS2*, and *SLC24A4*), AD (*SLC24A4* and *GABRG3*), acute lymphoblastic leukemia (*ERC2* and *ST6GALNAC3*), adiponectin levels (*CMIP* and *HIVEP2*), bipolar disorder and schizophrenia (*ERC2*), and type 2 diabetes (*PTPRD*).

###### Top 55 variants with *P* \< 1 × 10^−6^

  RSID            Chromosome   Position            Reference   Alternate   MAF       Effect size   SD        95% C.I.               *P*-value
  --------------- ------------ ------------------- ----------- ----------- --------- ------------- --------- ---------------------- -------------------
  *rs74944275*    *5*          *102*,*726*,*073*   *C*         *T*         *0.019*   *2.371*       *0.394*   *\[1.633*, *3.136\]*   *1.76* × *10^−9^*
  *rs10490263*    *2*          *40*,*973*,*289*    *C*         *T*         *0.469*   *0.697*       *0.116*   *\[0.483*, *0.932\]*   *2.15* × *10^−9^*
  *rs149372995*   *7*          *580*,*540*         *A*         *G*         *0.051*   *1.532*       *0.269*   *\[0.992*, *2.063\]*   *1.18* × *10^−8^*
  *rs140233081*   *7*          *580*,*735*         *C*         *A*         *0.056*   *1.396*       *0.255*   *\[0.926*, *1.898\]*   *4.26* × *10^−8^*
  rs139258867     11           33,422,464          C           T           0.017     2.487         0.461     \[1.593, 3.418\]       6.89 × 10^−8^
  rs11709639      3            94,975,203          T           A           0.325     0.645         0.120     \[0.415, 0.875\]       8.61 × 10^−8^
  rs75841969      12           127,335,883         G           A           0.052     1.464         0.275     \[0.921, 2.007\]       1.05 × 10^−7^
  rs72720587      4            137,323,780         C           T           0.019     2.328         0.441     \[1.515, 3.221\]       1.27 × 10^−7^
  rs2018116       14           92,831,272          T           C           0.768     0.636         0.121     \[0.383, 0.855\]       1.41 × 10^−7^
  rs141404567     11           33,393,524          G           A           0.017     2.514         0.481     \[1.634, 3.425\]       1.70 × 10^−7^
  rs2010568       2            118,395,972         G           C           0.429     0.646         0.125     \[0.385, 0.882\]       2.38 × 10^−7^
  rs144152209     7            585,369             C           A           0.060     1.349         0.262     \[0.879, 1.872\]       2.49 × 10^−7^
  rs74917009      5            169,915,787         G           A           0.027     1.971         0.382     \[1.233, 2.661\]       2.54 × 10^−7^
  rs144990130     7            582,328             G           A           0.061     1.324         0.257     \[0.849, 1.823\]       2.65 × 10^−7^
  rs12685122      9            9,206,006           T           G           0.211     0.867         0.169     \[0.534, 1.196\]       2.95 × 10^−7^
  rs73046027      3            19,950,385          C           T           0.132     0.963         0.188     \[0.624, 1.349\]       3.18 × 10^−7^
  rs7463321       8            20,523,821          T           C           0.167     0.860         0.168     \[0.523, 1.198\]       3.23 × 10^−7^
  rs148758667     9            130,665,077         G           T           0.060     1.456         0.285     \[0.949, 2.026\]       3.30 × 10^−7^
  rs72618491      3            94,938,828          G           A           0.335     0.606         0.119     \[0.363, 0.85\]        3.31 × 10^−7^
  rs117662279     7            155,362,626         G           A           0.018     2.214         0.434     \[1.328, 3.048\]       3.34 × 10^−7^
  rs1280103       4            187,526,002         C           A           0.396     −0.627        0.123     \[−0.878, −0.388\]     3.63 × 10^−7^
  rs7856285       9            18,973,653          G           A           0.609     0.612         0.120     \[0.366, 0.84\]        3.65 × 10^−7^
  rs17383917      3            94,984,650          T           C           0.330     0.640         0.126     \[0.401, 0.879\]       4.08 × 10^−7^
  rs11124760      2            41,001,812          C           T           0.437     0.639         0.126     \[0.394, 0.884\]       4.15 × 10^−7^
  rs61768273      1            44,509,818          A           T           0.034     1.790         0.354     \[1.074, 2.443\]       4.25 × 10^−7^
  rs17383687      3            94,963,466          C           T           0.329     0.653         0.129     \[0.412, 0.924\]       4.33 × 10^−7^
  rs12497549      3            20,072,654          C           T           0.157     0.898         0.178     \[0.528, 1.251\]       4.52 × 10^−7^
  rs36147593      15           27,587,764          A           G           0.110     1.119         0.222     \[0.684, 1.539\]       4.86 × 10^−7^
  rs10933941      3            94,965,589          G           A           0.329     0.635         0.126     \[0.392, 0.888\]       4.98 × 10^−7^
  rs116407196     5            102,973,337         A           G           0.035     1.804         0.360     \[1.129, 2.524\]       5.25 × 10^−7^
  rs7122488       11           21,874,253          T           C           0.646     0.633         0.126     \[0.402, 0.868\]       5.26 × 10^−7^
  rs12639003      3            94,966,599          A           G           0.329     0.637         0.127     \[0.39, 0.878\]        5.35 × 10^−7^
  rs12549162      8            20,547,331          C           G           0.167     0.872         0.174     \[0.538, 1.216\]       5.50 × 10^−7^
  rs62483581      7            106,726,214         G           A           0.451     0.587         0.117     \[0.367, 0.837\]       5.52 × 10^−7^
  rs12485639      3            94,940,998          C           A           0.320     0.604         0.121     \[0.359, 0.841\]       5.55 × 10^−7^
  rs67822265      2            53,715,939          C           T           0.289     0.665         0.133     \[0.401, 0.933\]       5.70 × 10^−7^
  rs17383861      3            94,983,399          G           A           0.331     0.635         0.127     \[0.396, 0.876\]       5.91 × 10^−7^
  rs9826288       3            95,044,652          C           T           0.665     −0.618        0.124     \[−0.855, −0.369\]     6.27 × 10^−7^
  rs2478319       13           48,111,575          A           G           0.689     0.596         0.120     \[0.358, 0.821\]       6.33 × 10^−7^
  rs72720573      4            137,257,730         T           C           0.018     2.416         0.485     \[1.488, 3.359\]       6.46 × 10^−7^
  rs140419591     11           33,327,476          A           G           0.017     2.516         0.506     \[1.553, 3.502\]       6.54 × 10^−7^
  rs78491489      7            44,335,828          C           T           0.113     0.934         0.188     \[0.61, 1.321\]        6.80 × 10^−7^
  rs6689933       1            76,837,471          C           T           0.684     0.633         0.128     \[0.401, 0.876\]       7.47 × 10^−7^
  rs17263248      3            55,574,820          A           G           0.200     0.804         0.163     \[0.5, 1.13\]          7.54 × 10^−7^
  rs10435819      9            9,197,298           G           A           0.194     0.849         0.172     \[0.49, 1.165\]        7.58 × 10^−7^
  rs61446477      3            94,964,689          A           G           0.329     0.639         0.129     \[0.38, 0.887\]        7.73 × 10^−7^
  rs72720589      4            137,333,269         T           A           0.017     2.233         0.452     \[1.326, 3.105\]       7.80 × 10^−7^
  rs7978950       12           47,361,547          C           T           0.412     0.611         0.124     \[0.382, 0.858\]       7.92 × 10^−7^
  rs2176276       3            94,989,440          C           A           0.329     0.613         0.124     \[0.389, 0.856\]       8.13 × 10^−7^
  rs1359665       13           48,097,289          G           A           0.684     0.642         0.130     \[0.384, 0.887\]       8.16 × 10^−7^
  rs4849593       2            118,369,787         G           A           0.407     0.652         0.132     \[0.404, 0.917\]       8.20 × 10^−7^
  rs72618501      3            94,974,822          T           C           0.330     0.633         0.129     \[0.398, 0.881\]       8.66 × 10^−7^
  rs61768270      1            44,498,974          C           T           0.034     1.788         0.364     \[1.134, 2.481\]       8.88 × 10^−7^
  rs1861305       2            40,950,582          A           G           0.468     0.589         0.120     \[0.356, 0.819\]       8.96 × 10^−7^
  rs4367173       4            7,383,470           C           G           0.195     −0.664        0.136     \[−0.92, −0.4\]        9.58 × 10^−7^

Variants in italics met a standard genome-wide significance of *P* \< 5 × 10^−8^. RSID, reference SNP cluster identifier; MAF, minor allele frequency.

![Effect sizes and consequences of top variants. (A) Allele frequencies and effect sizes for all variants with Bayes-GLMM-derived *P* \< 1 × 10^−6^. Positive-effect (*i.e.*, risk-increasing) loci are in red and negative-effect loci (*i.e.*, protective) are in blue. (B) Functional consequences of the top variants. MAF, minor allele frequency.](51fig5){#fig5}

The four genome-wide significant variants (*P* \< 5 × 10^−8^) were all intergenic: rs10490263, rs74944275, rs149372995, and rs140233081. These SNPs are located as follows: rs10490263 is 233,714 bp upstream of *SLC8A1* and 337 bp upstream of long intergenic noncoding RNA (lincRNA) *AC007317.1*; rs74944275 is 111,711 bp downstream of *C5orf30* and 18,568 bp downstream of lincRNA *CTD-2154H6.1*; rs140233081 and rs149372995 are in linkage disequilibrium (LD) and are located between *PRKAR1B* and *PDGFA*. Additionally, these final two SNPs are 8097 and 8292 bp downstream of *PRKAR1B*, and 21,254 and 21,059 bp upstream of *PDGFA*, respectively. To assess the functional relevance of the four variants, we queried the Roadmap Epigenomics ([@bib5]) and ENCODE ([@bib11]) resources using HaploReg ([@bib41]) for chromatin state and protein binding annotations. We found that rs10490263 lies in promoter-associated histone marks in the hippocampus and circulating T cells, and that rs74944275 lies in both promoter- and enhancer-associated histone marks in multiple brain regions. Furthermore, rs149372995 resides in a candidate-binding site of CTCF; rs74944275 resides in a candidate-binding site of CCNT2, Evi-1, GATA, and HDAC2; and rs140233081 and rs149372995 lie in candidate binding sites of NERF1a, SMC3, and TCF12.

Given the role of CTCF in genome organization and possible gene regulation, we further examined the flanking genes *PRKAR1B* and *PDGFA*. We localized the expression of the protein products of these two genes using immunofluorescence. Both PRKAR1B and PDGFA have widespread expression in the mouse brain, but are particularly localized to glia--vascular structures ([Figure 6](#fig6){ref-type="fig"}). This could be significant given the recent data suggesting glia--vascular alterations may predispose individuals to, or occur very early in, LOAD ([@bib2]; [@bib45]; [@bib32]). Furthermore, we evaluated RNA sequence data from the dorsolateral prefrontal cortex of participants in the ROS and Rush MAP studies, which are two longitudinal cohort studies of aging with prospective brain autopsy ([@bib3],[@bib4]; [@bib10]). In these human data, we found that higher *PDGFA* transcript level is moderately correlated with a greater neuritic plaque burden (*P* = 0.005, transcriptome-wide false discovery rate = 0.03; *β* \> 0) ([@bib29]), suggesting that the *PDGFA* association with AD may relate to a role in the accumulation of one of the two key pathologic features of AD.

![PDGFA and PRKAR1B localize to vascular structures in the mouse brain. PDGFA (red) shows close localization to (A) endothelial cells (CD31) and (B) basement membrane (COL-IV), components of the vascular substructure. (C) PRKAR1B (red) shows punctate expression in the region of blood vessels (CD31, green). See *Materials and Methods* for antibody details. Bar, 20 μm.](51fig6){#fig6}

Integrating prior knowledge {#s17}
---------------------------

Prior knowledge integration is a prominent feature of Bayesian modeling. In GWAS, prior information of a variant can be implemented with multiple strategies, each allowing posterior estimations to carry different weights of the priors. In brief, we considered the following strategies: (1) summary mean and SE estimated from a previous study, (2) normally distributed mean and inverse-gamma SE distributions based on prior estimates, (3) standardized mean (*t*-statistic) and inverse-gamma SE distributions based on prior estimates, and (4) normally distributed standardized mean (*t*-statistic) distribution and inverse-gamma SE distributions based on prior estimates (Table S3 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx)). In Bayes-GLMM, we implemented the fourth strategy to respect the unique challenges of GWAS, such as the different meanings of effect sizes from studies with different statistical models, variable allele frequencies in multiple study populations, and the particularly small *P*-values from large-scale studies. We considered priors from the International Genomics of Alzheimer's Project (IGAP) ([@bib28]). While none of the top 1000 IGAP variants were genome-wide significant in the ADSP data set, many showed suggestive significance and consistent effect directionality (Figure S5 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx)). However, drawing mean and SE priors directly from IGAP overwhelmed evidence in our study population and yielded significance estimates strongly correlated with IGAP results (Figure S6 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx)). Our method took the reported standardized effect sizes as the prior information and integrated them into the hierarchical model of each variant effect (*Materials and Methods*). To demonstrate the performance of this method, we generated a binary phenotypic trait (coded as 0 or 1) and genotypic trait of a variant (coded as 0, 1, or 2) by Monte Carlo, and used a logit-LM to test their associations. To illustrate the ability of Bayes-GLMM to integrate this information, we assessed the effect of prior information on the estimated variant effect by testing a range of prior standardized effect sizes. This method of prior configuration effectively modulates the information from the data ([Figure 7](#fig7){ref-type="fig"}), regardless of the differences between the prior information and the data in hand.

![Effects of priors on (A) posterior effect size, (B) posterior standardized error of the effect size, (C) posterior standardized effect size, and (D) posterior *P*-values. The *x*-axis denotes prior standardized effect size. The gray horizontal line in each graph is the respective posterior estimation when the prior standardized effect size is equal to 0. The two vertical dashed lines define a range of prior standardized effect sizes that increased the posterior *P*-value compared to a flat prior. Post, posterior.](51fig7){#fig7}

Discussion {#s18}
==========

We created a new GWAS method, Bayes-GLMM, and applied it to ADSP's WGS cohort. This method efficiently addresses three major challenges in GWAS: categorical phenotypes, population structure and sample relatedness, and prior knowledge integration. Furthermore, our generalized approach has the flexibility to operate on binary and quantitative traits in addition to ordered categorical phenotypes. These features enabled our identification of four new candidate variants in three loci that significantly increased the risk of AD.

Out of the four new genome-wide significant candidate variants, rs140233081 and rs149372995 are in LD and are located between *PRKAR1B* and *PDGFA*, which are potentially relevant to vascular dysfunction. Recent evidence suggests that vascular dysfunction is a critical component of AD pathology ([@bib2]; [@bib45]; [@bib32]) and potentially a necessary predisposing feature ([@bib20]). Further, vascular dysfunction has been shown to be necessary for the development of AD-like phenotypes in a mouse model of amyloid pathology ([@bib38]). We have localized PDGFA and PRKAR1B to specific components of vascular anatomy. Our immunofluorescence shows PDGFA expression between the collagen-rich tunica external and the endothelium of the tunica intima, supporting the presence of PDGFA in vascular smooth muscle cells (VSMCs). Previous studies have shown PDGF to affect VSMC proliferation by inducing a phenotypic switch from a contractile state to a proliferative one ([@bib36]). Insufficient PDGFA expression, then, may impair vascular regeneration following plaque-related insults, thereby exacerbating AD. This potential mechanism paired with increased *PDGFA* under amyloid burden expression suggests the two candidate variants could reduce necessary PDGFA expression when plaques are present, thereby attenuating the increase in *PDGFA* we observed with amyloid burden. PRKAR1B was seen in a punctate fashion, suggesting the presence of cytoplasmic clusters of the protein, and we hypothesize that the PRKAR1B puncta represent accumulation of protein kinase A (PKA) at either the endoplasmic reticulum or the insulin receptor. Calcium release from the endoplasmic reticulum is typically suppressed by phospholamban (PLN); however, such suppression is lifted following PLN phosphorylation by PKA. Changes in the regulation of calcium release due to altered *PRKAR1B* expression may very well have important consequences for AD, including but not limited to changes in vascular smooth muscle contraction that limit circulation to plaque-burdened brain regions. In addition to its calcium-related role, PKA is essential for signal transduction following activation of the insulin receptor, a process that has been shown to be the mechanism by which PDGF induces phenotypic switching in VSMCs ([@bib44]). In this way, changes in PRKAR1B may yield corresponding changes in circulation through suppressed arterial muscle contractility or through a direct influence on vascular growth and maintenance.

We consider our method, Bayes-GLMM, to be an important addition to the existing GWAS toolkit. The flexibility of Bayesian modeling allows the convenient configuration of sophisticated models, such as our GLMM. In Bayes-GLMM, logistic and ordered logistic regression likelihoods were used to model binary and ordered categorical variables, respectively. Conditional factors were included as model covariates and, although our study was underpowered for epistasis analysis, interaction terms can be straightforwardly included. Sample relatedness was modeled by a random term that followed a multivariate normal distribution. Model parameters can be estimated by either L-BFGS MLE or HMC sampling, as implemented in Stan.

Although the MLE implementation in Bayes-GLMM was efficient and reliable in estimating GLMs, it was unreliable in estimating GLMMs. We found that the MLE of the random term was skewed toward initial values, suggesting the optimizer was trapped into local optima and limiting reliability in estimating the GLMM. On the other hand, the MCMC sampler allows an improved assessment of the robustness and stability of model inferences by reporting the full posterior distributions of model parameters and the convergence of multiple sampling chains. This information allows one to dissect how multiple factors contribute to model estimation, including poorly defined prior distributions, collinearity of predictors, and inappropriate initial sampling values.

The Bayes-GLMM method was optimized in multiple ways to minimize the computational expense. It was optimized to (1) support parallel computing, (2) conjugate prior distributions, (3) vectorize model statements to exploit efficient matrix operations in Stan, and (4) parameterize multivariate normal distribution for the random effect by Cholesky factoring. Nevertheless, efficiency was still the primary drawback of MCMC sampling. When testing on a 2.3 GHz Intel processor, MLE took ∼0.12 sec to estimate the GLM per variant of the ADSP data set (*Materials and Methods*; [Figure 3](#fig3){ref-type="fig"}). In comparison, the MCMC sampler took ∼30 sec to generate 1000 samples for the same GLM, and 15 min to process 1000 samples for the GLMM model. Our prescan with MLE followed by more precise estimation by MCMC proved a practical approach to overcome these processing limitations when applying Bayes-GLMM in GWAS.

To reduce the computational burden in fitting GLMMs, we suggest that categorical diagnoses could be collapsed into binary variables. For the ADSP data, the "no" and "possible" diagnoses become "control," while the "probable" and "definite" diagnoses are "case." Logistic mixed models or binary mixed models were implemented in Bayes-GLMM to accommodate binary variables. The MCMC sampler implemented in Stan took ∼10 min to collect 1000 samples for parameters of such a binary mixed model, as opposed to 15 min for the four-level categorical mixed model. Alternatively, the recently released GMMAT (generalized linear mixed-model association test) method that used a penalized quasi-likelihood method to fit a binary mixed model was significantly faster than the MCMC sampling approach ([@bib8]). However, this practice of collapsing the categorical variable reduced precision due to the information loss in simplifying multiple categories. We tested this practice in the ADSP data and found the association results by binary GLMM and categorical GLMM showed substantial disagreement (Figure S7 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx)).

Another strategy to reduce computational requirements is to transform categorical variables into continuous variables to accommodate efficient LMM methods ([@bib25]; [@bib8]). However, this practice is prone to yield an incorrect type-I error rate because categorical studies do not satisfy LMM's constant residual variance assumption; that is, linear models assume residual variances are constant with respect to different values of model predictors. This practice also yields incorrect effect estimates due to the unbalanced sampling in different phenotypic categories, which is prominent in the ADSP study in which the probable diagnosis accounted for 62% of the total and the other three categories accounted for only 10--14%. We also found the inference results of LMM by QTLRel were sensitive to different quantitative coding of categorical variables (Figure S8 in [File S1](http://www.genetics.org/highwire/filestream/441937/field_highwire_adjunct_files/0/FileS1.docx); *Materials and Methods*). Taking rs34827707 as an example, the likelihood-ratio-test value for rs34827707 dropped from 29 to 15 when changing the coding from no/possible/probably/definite as 0/0.25/0.5/1 to 0/0.33/0.66/1. In contrast, the GLMM robustly estimated three cut points to separate the four categories.

Bayesian modeling naturally allows the integration of prior information by specifying the model parameter's prior distribution. However, how to best specify a variant's prior information is an open question when the prior study does not precisely match the experiment design in hand. Association results of each variant in a GWAS are commonly reported by effect size and *P*-value. While critical in describing the association strength, exact values of effect sizes are often specific to the given study because of dependencies on the statistical model, genotype coding strategies, and covariates. Therefore, it can be misleading to use the reported effect sizes to configure the priors. As opposed to effect sizes, *P*-values that quantify deviation from a null hypothesis can be less specific to the given study. However, *P*-values are strongly influenced by the sample size, and *P*-values from a large-scale study as priors would dominate the posterior estimation of a variant's association, thereby masking the information of the current study. To tackle this problem, we proposed a strategy that models the variant effect by a hierarchical model, in which variant effect was first modeled by a normal distribution with expected mean represented as the multiplication of the standardized expected mean and the SD. The standardized expected mean was further modeled by a standard normal with expected mean specified as the prior standardized effect. Simulation results showed our method of configuring the priors to be effective in allowing only priors modulating information of the data under study ([Figure 7](#fig7){ref-type="fig"}).

While powerful, Bayes-GLMM has several drawbacks. First, the quantitative meaning of parameter values is not readily interpretable in terms of fractional effects. Second, heritability estimation is elusive due to a difficulty in estimating residual variance. Third, as implemented, only one variance component is supported. Although Bayesian modeling can readily encompass multiple variance components, this becomes impractical for GWAS due to computational limitations for most researchers. Fourth, sampling-based estimations remain computationally intensive and may not be suitable for larger data sets (*e.g.*, the full set of ADSP variants). We expect that advances in model estimation techniques, improved algorithms, and broad application of cloud-based computational resources will alleviate these problems in the near future.

To summarize, here we have proposed a method for GWAS with three major features: (1) a generalized model to support multiple types of phenotypic data, (2) a Bayesian strategy to effectively integrate previous GWAS results for the same trait, and (3) a mixed-model implementation to correct population structure. With genome-wide association transitioning to whole-genome and whole-exome platforms, statistical methods for large-scale association studies are essential for uncovering the genetic basis of complex disease. The ability to integrate existing GWAS as prior information can further power these studies to prioritize specific variants at known loci.
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